Blackrock, INC Schedule 13G passive stakes
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a reduced beneficial ownership of 4.7% in Superior Group of Companies, Inc.
NYSE
BlackRock, Inc. has filed an Amendment No. 5 to its Schedule 13G, reporting a 2.5% beneficial ownership stake in Sutro Biopharma, Inc. as a passive investor.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 5.0% beneficial ownership stake in Wynn Resorts Ltd, totaling 5,178,283 common shares.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 7.0% Passive Stake in Avadel Pharmaceuticals
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 7.0% beneficial ownership stake in Avadel Pharmaceuticals' common stock as of June 30, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 4.99% Stake in Ardmore Shipping Corporation
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 4.99% of Ardmore Shipping Corporation's common stock as of June 30, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 1.5% passive beneficial ownership stake in Actinium Pharmaceuticals, Inc. as of June 30, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 6.6% Stake in SPYRE THERAPEUTICS INC
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.6% beneficial ownership stake in SPYRE THERAPEUTICS INC's common stock.
NYSE
BlackRock, Inc. has disclosed a 2.0% passive beneficial ownership stake in Adverum Biotechnologies, Inc., holding 414,485 shares of common stock as of June 30, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 4.9% Passive Stake in Alta Equipment Group
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.9% beneficial ownership stake in Alta Equipment Group Inc.'s Class A Stock as of June 30, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 7.6% Stake in Altimmune, Inc.
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.6% beneficial ownership stake in Altimmune, Inc.'s common stock.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 2.1% Passive Stake in Alto Neuroscience
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 2.1% passive beneficial ownership stake in Alto Neuroscience Inc.'s common stock.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 1.4% Stake in Amplify Energy Corp.
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 1.4% beneficial ownership in Amplify Energy Corp.'s common stock.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 5.5% Stake in Apogee Therapeutics
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 5.5% beneficial ownership stake in Apogee Therapeutics Inc., totaling 2,518,725 common shares.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 3.7% Passive Stake in Applied Therapeutics
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 3.7% beneficial ownership stake in Applied Therapeutics Inc., held as a passive investment.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 7.5% of Argan Inc.'s common stock as of June 30, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Reduces Stake in Aura Biosciences to 4.9%
BlackRock, Inc. has filed an amended Schedule 13G, reporting a reduction in its beneficial ownership stake in Aura Biosciences Inc. to 4.9% of common stock.
NYSE
SCHEDULE 13G/A: BlackRock Amends Passive Stake in Biomea Fusion to 1.3%
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 1.3% passive beneficial ownership stake in Biomea Fusion, Inc. as of June 30, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 2.0% Stake in Blink Charging Co.
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 2.0% beneficial ownership stake in Blink Charging Co. as of June 30, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 5.8% Passive Stake in Bumble Inc.
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 5.8% passive ownership stake in Bumble Inc.'s common stock.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 4.9% Passive Stake in CVR Energy Inc.
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.9% passive beneficial ownership stake in CVR Energy Inc. as of June 30, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 2.1% beneficial ownership stake in ChargePoint Holdings Inc. Class A Stock.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 4.6% Passive Stake in Compass Therapeutics
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.6% beneficial ownership stake in Compass Therapeutics, Inc. as of June 30, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 6.7% Stake in ConocoPhillips
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.7% beneficial ownership stake in ConocoPhillips common stock as of June 30, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.5% beneficial ownership stake in Contango Ore Inc.'s common stock as of June 30, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 2.9% Passive Stake in Corbus Pharmaceuticals
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 2.9% beneficial ownership stake in Corbus Pharmaceuticals Holdings Inc. as of June 30, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 4.6% Stake in 1-800-FLOWERS.COM
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.6% beneficial ownership stake in 1-800-FLOWERS.COM, Inc. as of June 30, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Amends Semler Scientific Stake Disclosure to 4.3%
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.3% beneficial ownership stake in Semler Scientific Inc. common stock.
NYSE
SCHEDULE 13G/A: BlackRock Amends SoundThinking Stake, Reports 4.9% Ownership
BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 4.9% beneficial ownership stake in SoundThinking, Inc. as of June 30, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.4% beneficial ownership stake in American Vanguard Corporation's common stock as of June 30, 2025.
NYSE
BlackRock, Inc. has reported a 7.8% beneficial ownership stake in Core Scientific, Inc., holding over 23 million shares of common stock.